CD200 attenuates methamphetamine-induced microglial activation and dopamine depletion

Abstract

This study examined the neuroprotective effect of cluster of differentiation molecule 200 (CD200) against methamphetamine (METH)-induced neurotoxicity. In the in vitro experiment, neuron-microglia cultures were treated with METH (20 μmol/L), METH (20 μmol/L)+CD200-Fc (10 μg/mL) or CD200-Fc (10 μg/mL). Those untreated served as control. Microglia activation expressed as the ratio of MHC-II/CD11b was assessed by flow cytometry. The cytokines (IL-1β, TNF-α) secreted by activated microglia were detected by enzyme-linked immunosorbent assay (ELISA). In the in vivo experiment, 40 SD rats were divided into control, METH, METH+CD200-Fc and CD200-Fc groups at random. Rats were intraperitoneally injected with METH (15 mg/kg 8 times at 12 h interval) in METH group, with METH (administered as the same dose and time as the METH group) and CD200-Fc (1 mg/kg at day 0, 2, 4 after METH injection) in METH+CD200-Fc group, with CD200-Fc (1 mg/kg injected as the same time as the METH+CD200-Fc group) or with physiological saline solution in the control group. The level of striatal dopamine (DA) in rats was measured by high-performance liquid chromatography (HPLC). The microglial cells were immunohistochemically detected for the expression of Iba-1, a marker for microglial activation. The results showed that METH could increase the microglia activation in the neuron-microglia cultures and elevate the secretion of IL-1β and TNF-α, which could be attenuated by CD200-Fc. Moreover, CD200-Fc could partially reverse the striatal DA depletion induced by METH and reduce the number of activated microglia, i.e. Iba-1-positive cells. It was concluded that CD200 may have neuroprotective effects against METH-induced neurotoxicity by inhibiting microglial activation and reversing DA depletion in striatum.

Keywords

methamphetamine / microglia / cluster of differentiation molecule 200 / dopamine / striatum

References

[1] United Nations Office on DrugsCrime.. . World drug report volume 1. Analysis, 2007, Vienna, United Nations Office on Drugs and Crime, 1-280

[2] FleckensteinA.E., VolzT.J., RiddleE.L., et al.. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol, 2007, 47(1): 681-698

[3] YamamotoB.K., RaudenskyJ.. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J Neuroimmune Pharmacol, 2008, 3(4): 203-217

[4] BowyerJ.F., RobinsonB., AliS., et al.. Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood-brain barrier in the caudate-putamen from acute methamphetamine exposure. Synapse, 2008, 62(3): 193-204

[5] YamamotoB.K., MoszczynskaA., GudelskyG.A.. Amphetamine toxicities classical and emerging mechanisms. Ann NY Acad Sci, 2010, 1187: 101-121

[6] LiuB., HongJ.S.. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther, 2003, 304(1): 1-7

[7] LaVoieM.J., CardJ.P., HastingsT.G.. Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol, 2004, 187(1): 47-57

[8] TocharusJ., KhonthunC., ChongthammakunS., et al.. Me latonin attenuates methamphetamine-induced overexpression of pro-inflammatory cytokines in microglial cell lines. J Pineal Res, 2010, 48(4): 347-352

[9] ThomasD.M., KuhnD.M.. MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Res, 2005, 1050(1–2): 190-198

[10] WebbM., BarclayA.N.. Localisation of the MRC OX-2 glycoprotein on the surfaces of neurons. J Neurochem, 1984, 43(4): 1061-1067

[11] NeumannH.. Control of glial immune function by neurons. Glia, 2001, 36(2): 191-199

[12] HoekR.M., RuulsS.R., MurphyC.A., et al.. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science, 2000, 290(5497): 1768-1771

[13] WangT., PeiZ., ZhangW., et al.. MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J, 2005, 19(9): 1134-1136

[14] GaoH.M., HongJ.S., ZhangW., et al.. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci, 2002, 22(3): 782-790

[15] KitaT., WagnerG.C., NakashimaT.. Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J Pharmacol Sci, 2003, 92(3): 178-195

[16] VolkowN.D., ChangL., WangG.J., et al.. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci, 2001, 21(23): 9414-9418

[17] VolkowN.D., ChangL., WangG.J., et al.. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry, 2001, 158(3): 377-382

[18] ThompsonP.M., HayashiK.M., SimonS.L., et al.. Structural abnormalities in the brains of human subjects who use methamphet Amine. J Neurosci, 2004, 24(26): 6028-6036

[19] CadetJ.L., LadenheimB., BaumI., et al.. CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxy methamphetamine (MDMA). Brain Res, 1994, 655(1–2): 259-262

[20] CadetJ.L., ShengP., AliS., et al.. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J Neurochem, 1994, 62(1): 380-383

[21] PuC., BroeningH.W., VorheesC.V.. Effect of methamphetamine on glutamate-positive neurons in the adult and developing rat somatosensory cortex. Synapse, 1996, 23(8): 328-334

[22] StephansS., YamamotoB.. Methamphetamine pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity. Neuroscience, 1996, 72(3): 593-600

[23] ItzhakY., GandiaC., HuangP.L., et al.. Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity. J Pharmacol Exp Ther, 1998, 284(3): 1040-1047

[24] ItzhakY., MartinJ.L., AliS.F.. Methamphetamine- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in inducible nitric oxide synthase-deficient mice. Synapse, 1999, 34(4): 305-312

[25] FloraG., LeeY.W., NathA. a., et al.. Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain. Exp Neurol, 2003, 179(1): 60-70

[26] PerryG., CashA.D., SmithM.A.. Alzheimer disease and oxidative stress. J Biomed Biotechnol, 2002, 2(3): 120-123

[27] TuppoE.E., AriasH.R.. The role of inflammation in Alzheimer’s disease. Int J Biochem Cell Biol, 2005, 37(2): 289-305

[28] ChintaS.J., AndersenJ.K.. Redox imbalance in Parkinson’s disease. Biochim Biophys Acta, 2008, 1780(11): 1362-1367

[29] KreutzbergG.W.. Microglia: a sensor for pathological events in the CNS. Trends Neurosci, 1996, 19(8): 312-318

[30] ThomasD.M., WalkerP.D., BenjaminsJ.A., et al.. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther, 2004, 311(1): 1-7

[31] Centers for Disease ControlPrevention-NIOSH Morgantown, West Biginia, USA.. Defining “neuroinflammation” lessons from MPTP- and methamphetamine-induced neurotoxicity. Ann NY Acad Sci, 2008, 1139(1): 318-330

[32] YoshimotoS., YasuomiO., GenichiS., et al.. Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci, 2008, 28(22): 5756-5761

[33] DavidM.T., DinaM.F., DonaldM.K.. Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling. J Neurochem, 2008, 106(2): 696-705

[34] OsamuK., ToshiakiT., ElaineL.W., et al.. Microglial and astroytic changes in the striatum of methamphetamine abusers. Leg Med, 2010, 12(2): 57-62

[35] HuangY.N., WuC.H., LinT.C., et al.. Methamphetamine induces hemeoxygenase-1 expression in cortical neurons and glia to prevent its toxicity. Toxicol Appl Pharmacol, 2009, 240(3): 315-326

[36] MelegaW.P., WilliamsA.E., SchmitzD.A., et al.. Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal. J Pharmacol Exp Ther, 1995, 274(1): 90-96

[37] ChitnisT., ImitolaJ., WangY., et al.. Elevated neuronal expression of CD200 protects wlds mice from inflammation-mediated neurodegeneration. Am J Pathol, 2007, 170(5): 1695-1712

[38] ZhangS., WangX.J., TianL.P., et al.. CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson’s disease. J Neuroinflammation, 2011, 8(6): 154

[39] BowyerJ.F., DaviesD.L., SchmuedL., et al.. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther, 1994, 268(3): 1571-1580

[40] BowyerJ.F., TankA.W., NewportG.D., et al.. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther, 1992, 260(2): 817-824

[41] MillerD.B., O’CallaghanJ.P.. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther, 1994, 270(2): 752-760

[42] O’CallaghanJ.P., MillerD.B.. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther, 1994, 270(2): 741-751

[43] GibbonsH., SatoT.A., DragunowM.. Hypothermia suppressesinducible nitric oxide synthase and stimulates cyclooxygenase-2 in lipopolysaccharide stimulated BV-2 cells. Brain Res Mol Brain Res, 2003, 110(1): 63-75

[44] KataokaK., YanaseH.. Mild hypothermia—A revived counter-measure against ischemic neuronal damages. Neurosci Res, 1998, 32(2): 103-117